Your session is about to expire
← Back to Search
Cabozantinib + Immunotherapy for Kidney Cancer (COSMIC-313 Trial)
COSMIC-313 Trial Summary
This trial is testing a new cancer drug, cabozantinib, to see if it is better than the current standard of care for advanced or metastatic renal cell carcinoma.
COSMIC-313 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCOSMIC-313 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 45 Patients • NCT02101736COSMIC-313 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain metastases have been treated and stable for at least 4 weeks.I have had treatment for advanced kidney cancer that couldn't be surgically removed.I do not have any active infections needing treatment, including hepatitis, HIV/AIDS, or tuberculosis.I do not have any serious recent illnesses affecting my heart, stomach, or lungs.I have had symptoms or treatment for an autoimmune disease in the last 2 years.I have fully healed from any major surgery over 4 weeks ago and any minor surgery over 10 days ago.My kidney cancer cannot be cured with surgery or radiation and has spread.My cancer can be measured and is not in an area treated by radiation.I haven't had radiation for bone metastasis in the last 2 weeks or any other radiation in the last 4 weeks.I have not received a live vaccine in the last 30 days.My organs and bone marrow are working well.I have no other active cancers or any treated within the last 3 years, except for certain skin, bladder, prostate, cervix, or breast cancers.My kidney cancer is considered intermediate or poor risk.I haven't taken high-dose steroids or other immune-weakening drugs in the last 2 weeks.I am able to care for myself but may not be able to do active work.I am currently taking blood thinners or platelet inhibitors.I had COVID-19 but recovered over 30 days ago.
- Group 1: Experimental Arm
- Group 2: Control Arm
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this new Cabozantinib research build on other existing studies?
"879 clinical trials are currently underway to study cabozantinib. Of these, 96 are in phase 3. Some of the trials for cabozantinib originate out of Pittsburgh, but there are 46877 total locations running trials for this medication."
Is Cabozantinib more harmful than other cancer treatments?
"Cabozantinib's safety is well-supported by clinical data, so it received a score of 3."
Are there any available positions for patients in this trial?
"No, this research is not recruiting patients at the moment. The most recent update on clinicaltrials.gov was from October 31st, 2022 and stated that the trial is no longer looking for participants. There are currently 3544 other trials that are actively enrolling patients though."
What are the standard treatments that Cabozantinib is used for?
"Cabozantinib can be used to treat otherwise inoperable melanoma, squamous cell carcinoma, and cases where there is a high risk of recurrence."
Are there numerous hospitals participating in this experiment within the confines of our state?
"Exelixis Clinical Site #64 in Fairfax, Exelixis Clinical Site #69 in Scarborough, and Exelixis Clinical Site #7A in Boston are just a few of the 36 locations where patients can enroll for this clinical trial."
How many participants are allowed to join this research project?
"This particular clinical trial is not currently looking for new participants. The posting was first published on June 25th, 2019 but the most recent edit occurred on October 31st, 2022. However, there are 2665 and 879 other trials respectively for patients with carcinoma and Cabozantinib that are presently recruiting."
Share this study with friends
Copy Link
Messenger